Qatari medical firm signs deal to import biotech drugs from Turkey

DOHA, Jan. 9 (Xinhua) -- Qatar's giant firm Ebn Sina Medical said it signed a distribution agreement with Turkish Company CinnaGen Ilac to import biotech drugs, local media reported Tuesday.

The signing ceremony was held on Monday in Doha and attended by the chief executive officers of both companies, in addition to the Turkish envoy to Qatar.

Under the agreement, the biotech drugs which will be exported from Turkey to Qatar are used for multiple sclerosis, rheumatoid arthritis, cancer and blood diseases.

"I am pleased to announce this partnership with a leading pharmaceutical firm such as CinnaGen Ilac. As we reveal this agreement, we express our determination and commitment to secure medicine availability in Qatar,'' said Sherif Shehata, general manager of Ebn Sina Medical.

Shehata also said the deal with CinnaGen Ilac came after a careful search for a well-establish partner in Turkey to provide his company with an excellent opportunity to expand its product offering.

In June 2017, Saudi Arabia, Egypt, the United Arab Emirates and Bahrain cut diplomatic ties with Qatar and all land, sea and air links to the tiny Gulf state.

As a result of the embargo, Qatar has established strong trade relationships with other countries, identified new markets and explored new channels for investment.

CinnaGen Co. was founded in 1994 in Iran and started to operate in Turkey in 2016.

As the leading pharmaceutical distribution company in Qatar, Ebn Sina Medical has signed exclusive distribution agreements with a number of international pharmaceutical companies. Enditem